Codeable Therapeutics

Codeable Therapeutics is a pre-clinical stage biotechnology company focused on developing the next generation of programmable genetic medicines. Founded by pioneers in the gene therapy field from the University of Pennsylvania, the company leverages a platform designed to code therapeutic instructions for precise in vivo cell engineering. Their technology aims to overcome current limitations in gene delivery and expression, providing more controlled and effective treatments for a variety of genetic disorders and oncology. Backed by prominent investors like ARCH Venture Partners and GV, Codeable is positioned at the intersection of synthetic biology and advanced genomic medicine. The company's approach focuses on engineering cells directly within the patient's body to simplify treatment and improve outcomes.